Abstract

.This study evaluated intermittent screening and treatment during pregnancy (ISTp) for malaria using rapid diagnostic tests (RDTs) at antenatal care (ANC) compared with passive case detection within the routine health system. The mixed-method evaluation included two cross-sectional household surveys (pre- and post-implementation of ISTp), in-depth interviews with health workers, and focus group discussions (FGDs) with pregnant women. Differences in proportions between surveys for a number of outcomes were tested; 553 and 534 current and recently pregnant women were surveyed (pre- and post-implementation, respectively). In-depth interviews were conducted with 29 health providers, and 13 FGDs were held with pregnant women. The proportion of pregnant women who received an RDT for malaria at ANC at least once during their pregnancy increased from pre- to post-implementation (19.2%; 95% CI: 14.9, 24.3 versus 42.5%; 95% CI: 36.6, 48.7; P < 0.0001), and the proportion of women who had more than one RDT also increased (16.5%; 95% CI: 13.1, 20.5 versus 27.7%; 95% CI: 23.0, 33.0; P = 0.0008). Post-implementation, however, only 8% of women who had completed their pregnancy received an RDT on three visits to ANC. Health workers were positive about ISTp mainly because of their perception that many pregnant women with malaria were asymptomatic. Health workers perceived pregnant women to have reservations about ISTp because of their dislike of frequent blood withdrawal, but pregnant women themselves were more positive. Intermittent screening and treatment during pregnancy was not sufficiently adopted by health workers to ensure the increased detection of malaria infections achievable with this strategy in this setting.

Highlights

  • Despite best efforts and tremendous progress, malaria continues to infect an estimated 212 million people annually, leading to approximately half a million deaths.[1]

  • The proportion of pregnant women who received an rapid diagnostic tests (RDTs) for malaria at antenatal care (ANC) at least once during their pregnancy increased from pre- to post-implementation (19.2%; 95% CI: 14.9, 24.3 versus 42.5%; 95% CI: 36.6, 48.7; P < 0.0001), and the proportion of women who had more than one RDT increased (16.5%; 95% CI: 13.1, 20.5 versus 27.7%; 95% CI: 23.0, 33.0; P = 0.0008)

  • P. falciparum malaria infections in pregnancy are associated with severe maternal anemia, fetal loss, and low birth weight (LBW), whereas P. vivax is associated with maternal anemia, LBW, and preterm births.[4,5,6]

Read more

Summary

Introduction

Despite best efforts and tremendous progress, malaria continues to infect an estimated 212 million people annually, leading to approximately half a million deaths.[1]. An estimated 88.2 of 125.2 million pregnancies (70%) in malariaendemic regions occur in the Asia-Pacific region each year, of which 28.2 million of those at risk of Plasmodium falciparum malaria and 32.9 million of those at risk of Plasmodium vivax occur in India.[3] The clinical effects of MiP depend on the level of transmission, the malaria species, and the level of immunity in pregnant women. P. falciparum malaria infections in pregnancy are associated with severe maternal anemia, fetal loss, and low birth weight (LBW), whereas P. vivax is associated with maternal anemia, LBW, and preterm births.[4,5,6]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call